<DOC>
	<DOCNO>NCT00171548</DOCNO>
	<brief_summary>Metabolic syndrome commonly define set risk factor abnormality markedly increase risk cardiovascular event . Its relevance confirm recent population-based survey subject age 40-79 year indicate prevalence metabolic syndrome Italy 34.1 % diagnose use WHO criteria 17.8 % diagnosed use NCEP-ATPIII criterion . On basis consideration , aim study promote use SCORE algorithm estimate cardiovascular risk , evaluate evolution patient metabolic syndrome implementation multifactorial preventive strategy , particular reference correction lifestyle , hypertension dyslipidemia .</brief_summary>
	<brief_title>Cardiovascular Risk Evaluation Clinical Practice Metabolic Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Patients gender age 4065 year . A diagnosis metabolic syndrome formulate basis criterion propose NCEP Adult Panel III : i.e . presence least three follow condition : 1 . Waist circumference &gt; 102 cm men &gt; 88 cm woman 2 . Triglyceridemia 150 mg/dl 3 . HDL cholesterol &lt; 40 mg/dl men &lt; 50 mg/dl woman 4 . Sitting arterial pressure 130/85 mmHg 5 . Fasting glycemia 110 mg/dl A risk cardiovascular death &gt; 5 % current age patient &gt; 5 % project age 60 year , calculate mean SCORE algorithm use table base total/HDL cholesterol ratio relate lowrisk population appropriate Italy . Written informed consent . Women menopause least one year surgically sterile , use effective contraceptive method , spermicidal barrier method intrauterine device . The use oral contraceptive allow . Known suspected hypersensitivity valsartan and/or fluvastatin , contraindication use ; A positive history ischemic heart disease , peripheral artery disease cerebral vasculopathy ; Patients SBP 180 mmHg and/or DBP 110 mmHg . Patients severe medical condition , judgement Investigator , contraindicate trial participation significantly limit life expectancy ; Treatment drug able modify lipid profile ( ongoing three month precede trial entry ) ; Patients unable follow plan protocol procedure sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Metabolic syndrome , cardiovascular risk reduction</keyword>
</DOC>